Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H. Lehmann-Che J, et al. Among authors: symmans wf. Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12. Oncologist. 2010. PMID: 20228131 Free PMC article. Clinical Trial.
Breast cancer biomarkers and molecular medicine.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Ross JS, et al. Among authors: symmans wf. Expert Rev Mol Diagn. 2003 Sep;3(5):573-85. doi: 10.1586/14737159.3.5.573. Expert Rev Mol Diagn. 2003. PMID: 14510178 Review.
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Ross JS, et al. Among authors: symmans wf. Mol Cell Proteomics. 2004 Apr;3(4):379-98. doi: 10.1074/mcp.R400001-MCP200. Epub 2004 Feb 3. Mol Cell Proteomics. 2004. PMID: 14762215 Free article. Review.
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Rajan R, et al. Among authors: symmans wf. Cancer. 2004 Apr 1;100(7):1365-73. doi: 10.1002/cncr.20134. Cancer. 2004. PMID: 15042669 Free article. Clinical Trial.
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL Jr, Drake RR, Vlahou A. Pusztai L, et al. Among authors: symmans wf. Cancer. 2004 May 1;100(9):1814-22. doi: 10.1002/cncr.20203. Cancer. 2004. PMID: 15112261 Free article.
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Ayers M, et al. Among authors: symmans wf. J Clin Oncol. 2004 Jun 15;22(12):2284-93. doi: 10.1200/JCO.2004.05.166. Epub 2004 May 10. J Clin Oncol. 2004. PMID: 15136595
302 results